Voyager Therapeutics Company Profile (NASDAQ:VYGR)

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $240.59 million
  • Outstanding Shares: 26,852,000
Average Prices:
  • 50 Day Moving Avg: $10.17
  • 200 Day Moving Avg: $12.03
  • 52 Week Range: $8.48 - $18.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.85 million
  • Price / Sales: 22.17
  • Book Value: $4.75 per share
  • Price / Book: 1.89
Profitability:
  • EBIDTA: ($50,560,000.00)
  • Net Margins: -195.31%
  • Return on Equity: -20.58%
  • Return on Assets: -15.23%
Debt:
  • Current Ratio: 9.96%
  • Quick Ratio: 9.96%
Misc:
  • Average Volume: 104,709 shs.
  • Beta: 4.04
  • Short Ratio: 10.62
 

Frequently Asked Questions for Voyager Therapeutics (NASDAQ:VYGR)

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by $0.11. The company had revenue of $1.46 million for the quarter, compared to analysts' expectations of $3.70 million. Voyager Therapeutics had a negative return on equity of 20.58% and a negative net margin of 195.31%. View Voyager Therapeutics' Earnings History.

Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?

7 brokerages have issued twelve-month target prices for Voyager Therapeutics' stock. Their predictions range from $13.00 to $37.00. On average, they expect Voyager Therapeutics' share price to reach $30.00 in the next year. View Analyst Ratings for Voyager Therapeutics.

What are analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/17/2017)
  • 2. Instinet analysts commented, "We are initiating on Voyager Therapeutics (VYGR) with a Buy rating and $31 target price. We anticipate updates from the ongoing trial of VY-AADC01 confirming efficacy, safety, and framing durability/duration of effect to drive upside in the share price over the next 12 months. In addition, we believe that data and initiation of a pivotal trial in advanced Parkinson's will attract investor attention, as the direct-to-CNS delivery of an enzyme becomes increasingly viewed as a risk-reduced approach to gene therapy with a rapidly addressable $1.5bn DBS-like market opportunity in advanced PD." (3/1/2017)
  • 3. Cowen and Company analysts commented, "This morning VYGR released an update from VY-AADC01’s Ph Ib in Parkinson’s." (1/20/2017)

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:

  • Mark J. Levin, Independent Chairman of the Board
  • Steven M. Paul M.D., President, Chief Executive Officer, Director
  • Jane Pritchett Henderson, Chief Financial Officer, Senior Vice President
  • Robert G. Pietrusko, Senior Vice President - Regulatory Affairs
  • Dinah Sah Ph.D., Chief Scientific Officer
  • Kathleen Hayes, Vice President - Human Resources
  • John J. Connelly, Vice President - Program and Alliance Management
  • Bernard Ravina M.D., Chief Medical Officer
  • Glenn F. Pierce M.D., Ph.D., Director
  • Wendy L. Dixon Ph.D., Independent Director

Who owns Voyager Therapeutics stock?

Voyager Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.01%), Vanguard Group Inc. (1.56%), Eventide Asset Management LLC (1.12%), JPMorgan Chase & Co. (0.61%), Wellington Management Group LLP (0.49%) and Fiduciary Trust Co. (0.40%). View Institutional Ownership Trends for Voyager Therapeutics.

Who sold Voyager Therapeutics stock? Who is selling Voyager Therapeutics stock?

Voyager Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., FMR LLC, JPMorgan Chase & Co., Morgan Stanley, Russell Investments Group Ltd. and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Voyager Therapeutics.

Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?

Voyager Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Vanguard Group Inc., Dimensional Fund Advisors LP, Wellington Management Group LLP, Fiduciary Trust Co., Bank of New York Mellon Corp, Geode Capital Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy Voyager Therapeutics stock?

Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of Voyager Therapeutics stock can currently be purchased for approximately $8.96.


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $30.00 (234.82% upside)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017WedbushReiterated RatingOutperform$36.00MediumView Rating Details
3/16/2017Chardan CapitalReiterated RatingNeutral -> Neutral$13.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/20/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/AView Rating Details
7/14/2016Stifel NicolausInitiated CoverageBuy -> Buy$33.00N/AView Rating Details
5/20/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Voyager Therapeutics (NASDAQ:VYGR)
Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Earnings History by Quarter for Voyager Therapeutics (NASDAQ VYGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
2017 EPS Consensus Estimate: ($2.47)
2018 EPS Consensus Estimate: ($3.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.67)($0.67)($0.67)
Q4 20171($0.74)($0.74)($0.74)
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.77)($0.77)($0.77)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Voyager Therapeutics (NASDAQ:VYGR)
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 39.95%
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Voyager Therapeutics (NASDAQ:VYGR)
Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
Source:
DateHeadline
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 2:58 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 17 at 9:38 AM
americanbankingnews.com logoWedbush Weighs in on Voyager Therapeutics Inc's Q2 2017 Earnings (VYGR)
www.americanbankingnews.com - May 12 at 7:52 AM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 9-May-17 9:30pm GMT
finance.yahoo.com - May 11 at 3:20 AM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 10 at 5:18 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - May 10 at 4:38 PM
marketbeat.com logoVoyager Therapeutics reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:24 AM
americanbankingnews.com logoZacks: Brokerages Expect Voyager Therapeutics Inc (VYGR) to Post -$0.54 Earnings Per Share
www.americanbankingnews.com - May 5 at 4:19 PM
finance.yahoo.com logoVoyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - May 5 at 3:36 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Earns Daily Media Impact Rating of -0.03
www.americanbankingnews.com - May 3 at 12:37 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 4:32 PM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receives Daily Coverage Optimism Rating of 0.17
www.americanbankingnews.com - April 30 at 8:52 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receiving Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 26 at 8:29 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Reports Additional Results from Phase 1b Trial of VY-AADC01
www.streetinsider.com - April 25 at 7:33 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Lowered to D+ at TheStreet
www.americanbankingnews.com - April 25 at 4:42 PM
finance.yahoo.com logoVoyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
finance.yahoo.com - April 25 at 8:44 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receives Daily News Impact Rating of -0.22
www.americanbankingnews.com - April 23 at 11:03 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Given News Sentiment Score of 0.15
www.americanbankingnews.com - April 20 at 3:04 PM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receiving Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 16 at 9:50 AM
americanbankingnews.com logo$3.7 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - April 16 at 8:26 AM
americanbankingnews.com logoShort Interest in Voyager Therapeutics Inc (VYGR) Expands By 4.8%
www.americanbankingnews.com - April 15 at 5:56 PM
americanbankingnews.com logo Analysts Expect Voyager Therapeutics Inc (VYGR) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 14 at 6:21 PM
americanbankingnews.com logoVoyager Therapeutics (VYGR) Receiving Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - April 13 at 1:16 PM
finance.yahoo.com logoVoyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : April 11, 2017
finance.yahoo.com - April 11 at 8:46 AM
finance.yahoo.com logoETFs with exposure to Voyager Therapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 1:27 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:46 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Given "Neutral" Rating at Chardan Capital
www.americanbankingnews.com - March 22 at 10:08 AM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 21 at 11:21 PM
finance.yahoo.com logoVoyager Therapeutics, Inc. (VYGR)
finance.yahoo.com - March 19 at 7:39 PM
finance.yahoo.com logoVOYAGER THERAPEUTICS, INC. Financials
finance.yahoo.com - March 18 at 7:35 PM
nasdaq.com logoPre-Market Earnings Report for March 15, 2017 : AIMT, ACRS, TWI, VYGR, AXAS, BXE, OFS, GTXI, NEON, CBK - Nasdaq
www.nasdaq.com - March 16 at 3:47 PM
seekingalpha.com logoVoyager Therapeutics' (VYGR) CEO Steven Paul on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 3:47 PM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 15-Mar-17 12:30pm GMT
finance.yahoo.com - March 16 at 3:47 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoVoyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights
us.rd.yahoo.com - March 16 at 6:43 AM
biz.yahoo.com logoVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
us.rd.yahoo.com - March 16 at 6:43 AM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 8:31 AM
finance.yahoo.com logoVoyager Therapeutics to Host Fourth Quarter and Full Year 2016 Financial Results Conference call
finance.yahoo.com - March 9 at 4:35 AM
finance.yahoo.com logoCoverage initiated on Voyager Therapeutics by Instinet
finance.yahoo.com - March 3 at 6:10 AM
finance.yahoo.com logoVoyager Therapeutics Supports Rare Disease Day® and Global Movement to Raise Awareness for Rare Diseases
finance.yahoo.com - February 28 at 11:07 AM
finance.yahoo.com logoVoyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - February 17 at 7:06 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Announces Lead Clinical Candidate Selection for Monogenic Form of ALS - StreetInsider.com
www.streetinsider.com - February 13 at 9:10 AM
feeds.benzinga.com logoVoyager Therapeutics to Attend Upcoming Investor Conferences
feeds.benzinga.com - February 2 at 11:40 AM
seekingalpha.com logoVoyager Therapeutics: Poised For Gains In 2017 - Seeking Alpha
seekingalpha.com - January 27 at 3:51 PM
nasdaq.com logoHershey Trust Co Buys JD.com Inc, Barracuda Networks Inc, Global Blood Therapeutics Inc
www.nasdaq.com - January 25 at 4:27 PM
us.rd.yahoo.com logoVoyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience
us.rd.yahoo.com - January 25 at 4:27 PM
finance.yahoo.com logo7:31 am Voyager Therapeutics announces updates regarding the Phase 1b trial of VY-AADC01 for patients with advanced Parkinson's disease; six-month efficacy results expected mid-2017
finance.yahoo.com - January 22 at 8:59 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease
www.streetinsider.com - January 21 at 1:39 AM
streetinsider.com logoVoyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease - StreetInsider.com
www.streetinsider.com - January 20 at 3:36 PM

Social

Chart

Voyager Therapeutics (VYGR) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff